Citi raised the firm’s price target on Bruker to $95 from $80 and keeps a Buy rating on the shares post the Q4 report. In a more challenged macroeconomic backdrop, Bruker has one of the better setups this year, driven by backlog insulation and margin progression with visibility on recent acquisitions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BRKR: